Market Research Report
Liquid Biopsy for Cancer Diagnostics - Competitive Landscape and Pipeline Analysis, 2022
|Liquid Biopsy for Cancer Diagnostics - Competitive Landscape and Pipeline Analysis, 2022|
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
DelveInsight's, "Liquid Biopsy for Cancer Diagnostics - Competitive Landscape and Pipeline Analysis, 2022," report provides an understanding of the current competition, pipeline products, and changing market dynamics of the Liquid Biopsy for Cancer Diagnostics market in the 7 major pharmaceutical markets. The report also gives a brief competitive analysis of both the current and emerging products, to help understand the competition in the market.
Liquid Biopsy for Cancer Diagnostics Understanding
Liquid Biopsy: Overview
Liquid biopsy is a revolutionary technique that consists of the detection and isolation of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes, as a source of genomic and proteomic information in patients with cancer. The major advantages of liquid biopsy in cancer diagnosis is that the technique is minimally-invasive, painless, does not have risk of complications, and gives faster results as compared to tumor biopsies. Some disadvantages and limitations of liquid biopsy include its lower accuracy and sensitivity as compared to tumor biopsies, and a lack of standardized protocols for isolation of components from the blood for mutation analysis.
Why use Liquid Biopsy instead of Tissue Biopsy?
Liquid Biopsy: Competitive Assessment
This segment of the report provides a brief competitive analysis of both the current and emerging products, to help understand the competition in the market. It has been segregated based on following parameters that define the scope of the report, such as:
DelveInsight's report covers around approx. 20 major products segregated under marketed and emerging
DelveInsight's Liquid Biopsy for cancer diagnostics report provides a complete analysis of all the major collaborations done by the key players for the development of the liquid biopsy test devices
Further collaboration details are provided in the report…….
Products have been categorized under various turnaround time such as:
Products have been categorized under different indications under the Cancer therapeutics such as:
Products have been classified according to the different biomarker types used in the detection of cancer through liquid Biopsy technique:
There are approx. 20+ key companies which are developing the products for liquid biopsy products.
Grail is developing multi-cancer early detection liquid biopsy test or blood test which can detect up to 50 types of cancer and is committed to is committed to develop a deep understanding of cancer biology. GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. GRAIL is creating vast datasets to develop evidence supporting their products.
ANGLE's Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer. Parsortix is different from many of its rivals as, rather than testing for fragments of dead cancer cells, it detects and captures circulating tumour cells (CTCs). CTCs provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options. This method is seen as more reliable because other tests have shown that fragments of dead cancer cells are present in around a quarter of people over 65 who do not have cancer. CTCs, on the other hand, give a complete picture because they can only be found in people with cancer.
Exact's DNA methylation based liquid biopsy test detects 80% of hepatocellular carcinoma (HCC) cases across all stages and 71% of early stage cases. It has shown better performance than the most commonly used marker for HCC, serum alpha-fetoprotein (AFP).
Liquid Biopsy for Cancer Diagnostics: Commercialization Activity
This segment of the report provides a detailed list of any commercial activity in the field of liquid biopsy products ranging from collaboration, mergers and acquisition, recent breakthrough among others.
Further commercial activities are provided in the report……..
Liquid Biopsy for Cancer Diagnostics: Regulatory Pathway
Liquid Biopsy: Regulatory Overview
The regulatory pathway for diagnostic is an alternative NDA process for approving a new diagnostic device. This segment provides an overview of how the regulatory bodies such as the FDA the diagnostics products, by classifying them into different classes which are Class I, II, or III according to the level of regulatory control that is necessary to reasonably assure safety and effectiveness.